Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07645651
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic CancerCarrick Therapeutics LimitedNot Yet RecruitingPhase 1
NCT07645651Not Yet Recruiting
Phase 1
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectabl...Carrick Therapeutics Limi...
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D CompanyNot Yet RecruitingPhase 1
NCT07645222Not Yet Recruiting
Phase 1
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D Com...
NCT07646483
Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and Second Cycle (Repeat) Administration in Patients With Knee OsteoarthritisPharmaResearch Co.,LtdNot Yet RecruitingNot Applicable
NCT07646483Not Yet Recruiting
Not Applicable
Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and...PharmaResearch Co.,Ltd
NCT07644208
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative HepatectomyShanghai Zhongshan HospitalNot Yet RecruitingPhase 2
NCT07644208Not Yet Recruiting
Phase 2
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatoc...Shanghai Zhongshan Hospit...
NCT07645287
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Gilead SciencesNot Yet RecruitingPhase 2
NCT07645287Not Yet Recruiting
Phase 2
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologica...Gilead Sciences
NCT07645339
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier RepairL'OrealActive Not RecruitingNot Applicable
NCT07645339Active Not Recruiting
Not Applicable
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Barrier...L'Oreal
NCT07645781
Cervical Stabilization Exercises IN Subacromial Impingement SyndromeCairo UniversityNot Yet RecruitingNot Applicable
NCT07645781Not Yet Recruiting
Not Applicable
Cervical Stabilization Exercises IN Subacromial Impingement SyndromeCairo University
NCT07646535
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismShenzhen Salubris Pharmaceuticals Co., Ltd.Not Yet RecruitingPhase 2
NCT07646535Not Yet Recruiting
Phase 2
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses i...Shenzhen Salubris Pharmac...
NCT07643818
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron DeficiencyGovernment of JerseyNot Yet RecruitingPhase 2
NCT07643818Not Yet Recruiting
Phase 2
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in H...Government of Jersey
NCT07645495
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07645495Not Yet Recruiting
Not Applicable
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef University
NCT07645807
An Investigator-Initiated, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.Sichuan Credit Pharmaceutical Co., Ltd.Not Yet RecruitingNot Applicable
NCT07645807Not Yet Recruiting
Not Applicable
An Investigator-Initiated, Randomized, Double-Blind, Double-Dummy Study to Evalu...Sichuan Credit Pharmaceut...
NCT07644533
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced CancerAffiliated Hospital of Qinghai UniversityNot Yet RecruitingNot Applicable
NCT07644533Not Yet Recruiting
Not Applicable
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in...Affiliated Hospital of Qi...
NCT07644351
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia PatientsNovartis PharmaceuticalsCompleted
NCT07644351Completed
—
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lym...Novartis Pharmaceuticals
NCT07644442
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmedCompletedPhase 1
NCT07644442Completed
Phase 1
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmed
NCT07645950
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Montpellier - Val d'AurelleNot Yet Recruiting
NCT07645950Not Yet Recruiting
—
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Mon...
NCT07645378
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South AfricaCentre for the AIDS Programme of Research in South AfricaNot Yet RecruitingNot Applicable
NCT07645378Not Yet Recruiting
Not Applicable
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervica...Centre for the AIDS Progr...
NCT07646028
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLCNot Yet RecruitingPhase 1
NCT07646028Not Yet Recruiting
Phase 1
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLC
NCT07646366
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee OsteoarthritisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646366Not Yet Recruiting
Not Applicable
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee O...Riphah International Univ...
NCT07644455
Percutaneous Biopsy After Neoadjuvant Chemotherapy.Instituto do Cancer do Estado de São PauloNot Yet RecruitingNot Applicable
NCT07644455Not Yet Recruiting
Not Applicable
Percutaneous Biopsy After Neoadjuvant Chemotherapy.Instituto do Cancer do Es...
Result Breakdown
Not yet recruiting16 (80%)
Completed3 (15%)
Active, not recruiting1 (5%)
not_applicable9 (45%)
Phase 15 (25%)
Phase 24 (20%)
Not Specified2 (10%)